BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
People with depression can treat themselves at home with new device - 2Most loved Public Dish: Which One Addresses Its Nation Best?
- 3Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 4Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600
- 5Instructions to Explore the Universe of Vehicle Leases
- Best Pizza Beating: What's Your #1?
- James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
- Top Frozen yogurt Flavor: Cast Your Vote!
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- The Most Vital Crossroads in Olympic History
- Investigating Cooking and Culinary Expressions: An Excursion Through Flavors
- A Manual for SUVs with Less Noteworthy Gas Mileage
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
